GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (LTS:0HF9) » Definitions » Other Operating Expense

Amicus Therapeutics (LTS:0HF9) Other Operating Expense : $8.7 Mil (TTM As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Amicus Therapeutics Other Operating Expense?

Amicus Therapeutics's Other Operating Expense for the three months ended in Jun. 2024 was $2.2 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 was $8.7 Mil.

Amicus Therapeutics's quarterly Other Operating Expense declined from Dec. 2023 ($2.2 Mil) to Mar. 2024 ($2.2 Mil) but then increased from Mar. 2024 ($2.2 Mil) to Jun. 2024 ($2.2 Mil).

Amicus Therapeutics's annual Other Operating Expense declined from Dec. 2021 ($6.2 Mil) to Dec. 2022 ($5.3 Mil) but then increased from Dec. 2022 ($5.3 Mil) to Dec. 2023 ($7.9 Mil).


Amicus Therapeutics Other Operating Expense Historical Data

The historical data trend for Amicus Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Other Operating Expense Chart

Amicus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.78 8.85 6.21 5.34 7.87

Amicus Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.21 2.23 2.18 2.15 2.18

Amicus Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amicus Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Amicus Therapeutics Business Description

Traded in Other Exchanges
Address
3675 Market Street, Philadelphia, PA, USA, 19104
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics Headlines

No Headlines